The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 3

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma   Host: Gerald B. Lee, MD, FACAAI Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI   Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.   Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity Reference:Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.   Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose   Leonard B. Bacharier, MD, FACAAI Advisor: DBV Technologies Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi Researcher: AstraZeneca, Sanofi Speaker: Regeneron, Sanofi   Alan P. Baptist, MD, MPH, FACAAI Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Researcher: AstraZeneca, Novartis, Regeneron   This podcast miniseries is supported by a grant from AstraZeneca.